Analyst Coverage

Disclaimer: Any opinions, estimates or forecasts regarding ResApp Health Limited’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResApp Health Limited or its management. ResApp Health Limited does not by its reference to any analysts imply its endorsement of or concurrence with such information, conclusions or recommendations.

Morgans Financial July 7, 2017 What’s in a cough
NDF Research June 30, 2017 First major clinical study of ResAppDx reports important data
Patersons Securities June 9, 2017 Market Update
Patersons Securities March 1, 2017 1H17 Result, Waiting on FDA Trial Data
Patersons Securities November 16, 2016 Initiating Coverage
Bioshares August 19, 2016 Telemedicine Adoption Building
NDF Research July 25, 2016 Initiation of Coverage
DJ Carmichael April 4, 2016 Emerging ASX Technology Sector
DJ Carmichael October 19, 2015 Emerging ASX Technology Sector
Bioshares October 9, 2015 Good Early Data for ResApp
Bioshares August 28, 2015 TeleMedicine is on the Move
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.